No Data
Livzon Pharma (01513): The fund-raising investment project has been completed and the remaining fund will be permanently used to supplement working capital.
Livzon Pharma (01513) announced that Livzon Pharma Group Co., Ltd. (hereinafter referred to as the "Company") held the nineteenth meeting of the eleventh board of directors and the tenth meeting of the eleventh board of supervisors on September 27, 2024.
Livzon Pharma (01513) spent approximately 5.4011 million yuan to buy back 0.153 million shares of A-shares on September 18th.
Livzon Pharma (01513) announced that on September 18, 2024, it spent approximately 5.4011 million yuan to repurchase 15.3...
Will Weakness in Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Stock Prove Temporary Given Strong Fundamentals?
Livzon Pharmaceutical Group Inc. expects reduced performance pressure in the second half of the year | Live coverage of the earnings conference
① At the results meeting, Yang Liang, director of Lizhu Group, responded to issues such as the year-on-year decline in the company's revenue and financial data in various segments; ② Tang Yanggang, president of the company, said that the overall market size of tocilizumab injections in China is small.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings YetNo Data
No Data
